VAXXINITY INC-A (VAXX) Stock Price, Forecast & Analysis
USA - NASDAQ:VAXX - US92244V1044 - Common Stock
VAXX Key Statistics, Chart & Performance
The current stock price of VAXX is 0.1111 USD. In the past month the price decreased by -81.79%. In the past year, price decreased by -94.42%.
VAXX Latest News, Press Relases and Analysis
VAXX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About VAXX
Company Profile
Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company is headquartered in Dallas, Texas and currently employs 87 full-time employees. The company went IPO on 2021-11-11. The firm is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) has enabled the innovation of pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimers, Parkinsons, migraine, and hypercholesterolemia. Its pipeline consists of six programs, which include UB-311, UB-312, VXX-301, UB-313, VXX-401 and UB-612. Its UB-311 targets toxic forms of aggregated amyloid-b (Ab) in the brain to fight AD. Its UB-312 targets toxic forms of aggregated a-synuclein in the brain to fight PD and other synucleinopathies, such as Lewy body dementia (LBD) and multiple system atrophy (MSA). Its UB-313 targets Calcitonin Gene-Related Peptide (CGRP) to fight migraines.
Company Info
VAXXINITY INC-A
1717 Main Street, Suite 3388
Dallas TEXAS US
Employees: 87
Phone: 12542445739
VAXXINITY INC-A / VAXX FAQ
Can you describe the business of VAXXINITY INC-A?
Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company is headquartered in Dallas, Texas and currently employs 87 full-time employees. The company went IPO on 2021-11-11. The firm is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) has enabled the innovation of pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimers, Parkinsons, migraine, and hypercholesterolemia. Its pipeline consists of six programs, which include UB-311, UB-312, VXX-301, UB-313, VXX-401 and UB-612. Its UB-311 targets toxic forms of aggregated amyloid-b (Ab) in the brain to fight AD. Its UB-312 targets toxic forms of aggregated a-synuclein in the brain to fight PD and other synucleinopathies, such as Lewy body dementia (LBD) and multiple system atrophy (MSA). Its UB-313 targets Calcitonin Gene-Related Peptide (CGRP) to fight migraines.
What is the current price of VAXX stock?
The current stock price of VAXX is 0.1111 USD. The price decreased by -15.26% in the last trading session.
Does VAXXINITY INC-A pay dividends?
VAXX does not pay a dividend.
What is the ChartMill rating of VAXXINITY INC-A stock?
VAXX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for VAXX stock?
8 analysts have analysed VAXX and the average price target is 15.3 USD. This implies a price increase of 13671.38% is expected in the next year compared to the current price of 0.1111.
What is VAXXINITY INC-A worth?
VAXXINITY INC-A (VAXX) has a market capitalization of 14.08M USD. This makes VAXX a Nano Cap stock.
Can you provide the upcoming earnings date for VAXXINITY INC-A?
VAXXINITY INC-A (VAXX) will report earnings on 2024-08-07, after the market close.
VAXX Technical Analysis
VAXX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to VAXX. Both the profitability and financial health of VAXX have multiple concerns.
VAXX Financial Highlights
Over the last trailing twelve months VAXX reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS increased by 25.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -128.51% | ||
| ROE | -424.66% | ||
| Debt/Equity | 0.99 |
VAXX Forecast & Estimates
8 analysts have analysed VAXX and the average price target is 15.3 USD. This implies a price increase of 13671.38% is expected in the next year compared to the current price of 0.1111.